Wu Liuhong

and 10 more

Lian Zhang

and 12 more

Xiaoqin Zhu

and 12 more

Objective: We investigated the influence of methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms on the survival of pediatric non-Hodgkin lymphoma (NHL) cases in south China treated with the modified Berlin-Frankfurt-Münster 95 protocol. Methods: We reviewed the medical records of 374 patients newly diagnosed at our center between 2014 and 2020. A subgroup of 158 patients was genotyped based on polymorphisms C677T and A1298C. Results: Overall, there were 283 male (75.7%) and 91 female patients (24.3%); the median age was 9 years (range, 1–18 years). The tumor types included Burkitt lymphoma (BL; n = 180), lymphoblastic lymphoma (LBL; n = 95), anaplastic large cell lymphoma (ALCL; n = 64), and diffuse large B cell lymphoma (DLBCL; n = 35). At diagnosis, 327 patients (87.4%) had advanced-stage disease; 159 (42.5%) and 152 patients (40.6%) were stratified into the intermediate- and high-risk group, respectively. Seventy (18.7%) and 36 cases (9.6%) had bone marrow and central nervous system (CNS) involvement, respectively. The median follow-up time was 28.5 months (range, 1–76 months); complete remission rate, estimated 5-year event-free survival, and 5-year overall survival rate was 86.1%, 74.2%, and 85.7%, respectively. The C677T variant allele was correlated with favorable survival in BL/DLBCL, while ALCL, CNS involvement, advanced stage, and intermediate/high risk were associated with poor survival in NHL. Conclusion: Analysis of the C677T polymorphism could be used for survival prediction and potential risk stratification for further treatment protocols for Chinese pediatric NHL. Further larger studies are needed to verify the clinical value of the C677T polymorphism.

Lei Mao

and 10 more

Background. The criteria for response evaluation in pediatric and adolescent Hodgkin lymphoma (HL) are controversial. We compared different criteria for the interpretation of interim and post-treatment PET/CT to predict the outcome of pediatric and adolescent HL. Procedure. Baseline, interim, and post-treatment 18F-FDG-PET/CT scans of 147 pediatric and adolescent HL patients were interpreted according to the International Harmonization Project Criteria (IHPC) and Deauville Criteria (DC). Two thresholds of positivity were used for the DC: DC-3, scores of 3–5; and DC-4, scores of 4–5. Diagnostic performance of interim and post-treatment PET in outcome prediction was evaluated. Progression-free survival (PFS) was analyzed by the Kaplan-Meier method and Cox proportional hazards model. Results. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of interim FDG-PET/CT were 82%, 33%, 15%, 93%, and 39%, respectively, for IHPC, 82%, 51%, 19%, 95%, and 55%, respectively, for DC-3, and 27%, 78%, 15%, 88%, and 72%, respectively, for DC-4. The corresponding values for post-treatment PET/CT were 73%, 74%, 23%, 96%, and 74% for IHPC, 67%, 80%, 27%, 96%, and 79% for DC-3, and 47%, 90%, 33%, 94%, and 86% for DC-4. PFS significantly differed between patients with positive and negative post-treatment PET/CT according to IHPC, DC-3, and DC-4 (P < 0.01 for all), but only DC-4 was an independent prognostic factor for PFS (hazard ratio: 7.82). Conclusion. Compared to interim PET/CT, post-treatment PET/CT better predicted the outcomes of pediatric and adolescent HL. DC-4 had superior diagnostic performance over IHPC and DC-3.